A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).

NCT00768079 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

110

Enrollment

INDUSTRY

Sponsor class

Conditions

Asthma

Interventions

OTHER: Placebo
BIOLOGICAL: Benralizumab

Sponsor

MedImmune LLC